{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:02:51Z","timestamp":1792026171464,"version":"4.4.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"SI","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>IL-34 is a haematopoietic cytokine that promotes macrophage activation. Macrophage activation in interstitial lung disease (ILD) in patients with DM, especially in those with anti-melanoma differentiation-associated gene 5 (MDA5) antibody suggests the involvement of IL-34 in the disease. However, the association between IL-34 and DM is unknown. In this study, we aimed to determine serum IL-34 levels in DM patients and evaluate their association with DM-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We measured serum IL-34 levels in 56 DM patients and 14 age- and sex- matched healthy controls by ELISA, and examined their correlation with clinical parameters. In addition, pre- and post-treatment serum IL-34 levels were examined using serum samples from 7 anti-MDA5 antibody-positive DM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serum IL-34 levels were significantly elevated in DM patients, especially in those with anti-MDA5 antibody, compared with healthy controls. In anti-MDA5-antibody-positive DM patients, serum IL-34 levels positively correlated with serum levels of ferritin and anti-MDA5 antibody, which are known biomarkers for rapidly progressive (RP)-ILD. Following combined immunosuppressive therapy, serum IL-34 levels decreased along with ferritin and anti-MDA5 antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data suggest that IL-34 may be involved in the development of RP-ILD in anti-MDA5 antibody-positive DM. Serum IL-34 levels can serve as a potential biomarker for RP-ILD in this clinical entity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae313","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T09:00:44Z","timestamp":1717232444000},"page":"SI97-SI104","source":"Crossref","is-referenced-by-count":3,"title":["Serum interleukin-34 levels in dermatomyositis: a potential biomarker for anti-MDA5-antibody-associated interstitial lung disease"],"prefix":"10.1093","volume":"64","author":[{"given":"Ai","family":"Kuzumi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, University of Tokyo Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemichi","family":"Fukasawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, University of Tokyo Graduate School of Medicine , Tokyo,","place":["Japan"]},{"name":"Department of Clinical Cannabinoid Research, University of Tokyo Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, University of Tokyo Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki M","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, University of Tokyo Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Kotani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, University of Tokyo Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Yoshizaki-Ogawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, University of Tokyo Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, University of Tokyo Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-9140","authenticated-orcid":false,"given":"Ayumi","family":"Yoshizaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, University of Tokyo Graduate School of Medicine , Tokyo,","place":["Japan"]},{"name":"Department of Clinical Cannabinoid Research, University of Tokyo Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"2025121017321765400_keae313-B1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"2025121017321765400_keae313-B2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025121017321765400_keae313-B3","doi-asserted-by":"crossref","first-page":"1255540","DOI":"10.3389\/fimmu.2023.1255540","article-title":"Comprehensive autoantibody profiling in systemic autoimmunity by a highly-sensitive multiplex protein array","volume":"14","author":"Kuzumi","year":"2023","journal-title":"Front Immunol"},{"key":"2025121017321765400_keae313-B4","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025121017321765400_keae313-B5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"2025121017321765400_keae313-B6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1126\/science.1154370","article-title":"Discovery of a cytokine and its receptor by functional screening of the extracellular proteome","volume":"320","author":"Lin","year":"2008","journal-title":"Science"},{"key":"2025121017321765400_keae313-B7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/JLB.MR1117-457R","article-title":"Interleukin-34, a comprehensive review","volume":"104","author":"Baghdadi","year":"2018","journal-title":"J Leukoc Biol"},{"key":"2025121017321765400_keae313-B8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2011-200096","article-title":"Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients","volume":"71","author":"Chemel","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025121017321765400_keae313-B9","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/art.41792","article-title":"Interleukin-34 reprograms glycolytic and osteoclastic rheumatoid arthritis macrophages via syndecan 1 and macrophage colony-stimulating factor receptor","volume":"73","author":"Van Raemdonck","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025121017321765400_keae313-B10","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/1346-8138.14538","article-title":"Serum interleukin-34 levels in patients with systemic sclerosis: clinical association with interstitial lung disease","volume":"45","author":"Kuzumi","year":"2018","journal-title":"J Dermatol"},{"key":"2025121017321765400_keae313-B11","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/art.41798","article-title":"B cell depletion inhibits fibrosis via suppression of profibrotic macrophage differentiation in a mouse model of systemic sclerosis","volume":"73","author":"Numajiri","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025121017321765400_keae313-B12","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","article-title":"Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis","volume":"12","author":"Kuzumi","year":"2021","journal-title":"Nat Commun"},{"key":"2025121017321765400_keae313-B13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamadermatol.2022.6340","article-title":"Long-term outcomes after rituximab treatment for patients with systemic sclerosis: follow-up of the DESIRES trial with a focus on serum immunoglobulin levels","volume":"159","author":"Kuzumi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025121017321765400_keae313-B14","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1038\/s41598-018-21859-z","article-title":"Elevated serum interleukin-34 level in patients with systemic lupus erythematosus is associated with disease activity","volume":"8","author":"Xie","year":"2018","journal-title":"Sci Rep"},{"key":"2025121017321765400_keae313-B15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2018090901","article-title":"IL-34-dependent intrarenal and systemic mechanisms promote lupus nephritis in MRL-Fas(lpr) mice","volume":"30","author":"Wada","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2025121017321765400_keae313-B16","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/rheumatology\/kes435","article-title":"IL-34 is overexpressed in the inflamed salivary glands of patients with Sjogren's syndrome and is associated with the local expansion of pro-inflammatory CD14(bright)CD16+ monocytes","volume":"52","author":"Ciccia","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2025121017321765400_keae313-B17","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2025121017321765400_keae313-B18","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1080\/14397595.2018.1548918","article-title":"Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis","volume":"29","author":"Nishioka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2025121017321765400_keae313-B19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/rheumatology\/kez301","article-title":"Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis\/dermatomyositis-interstitial lung disease","volume":"59","author":"Matsuda","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025121017321765400_keae313-B20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-016-1214-8","article-title":"Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease","volume":"19","author":"Enomoto","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025121017321765400_keae313-B21","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/kez185","article-title":"Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD","volume":"58","author":"Horiike","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025121017321765400_keae313-B22","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1093\/rheumatology\/keaa034","article-title":"Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis","volume":"59","author":"Zuo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025121017321765400_keae313-B23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2025121017321765400_keae313-B24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2025121017321765400_keae313-B25","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2025121017321765400_keae313-B26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025121017321765400_keae313-B27","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keq073","article-title":"Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2025121017321765400_keae313-B28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cia2.12169","article-title":"Rapidly progressive interstitial lung disease associated with dermatomyositis\u2014longitudinal course of anti-MDA5 antibody titer in two cases","volume":"4","author":"Awaji","year":"2021","journal-title":"J Cutaneous Immunol Allergy"},{"key":"2025121017321765400_keae313-B29","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","author":"American Thoracic Society","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121017321765400_keae313-B30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12016-015-8496-5","article-title":"Cutaneous manifestations in dermatomyositis: key clinical and serological features-a comprehensive review","volume":"51","author":"Muro","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025121017321765400_keae313-B31","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2025121017321765400_keae313-B32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025121017321765400_keae313-B33","doi-asserted-by":"crossref","first-page":"e81665","DOI":"10.1371\/journal.pone.0081665","article-title":"The newly discovered cytokine IL-34 is expressed in gingival fibroblasts, shows enhanced expression by pro-inflammatory cytokines, and stimulates osteoclast differentiation","volume":"8","author":"Bostr\u00f6m","year":"2013","journal-title":"PLoS One"},{"key":"2025121017321765400_keae313-B34","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00296-010-1688-7","article-title":"Proinflammatory cytokines, IL-1\u03b2 and TNF-\u03b1, induce expression of interleukin-34 mRNA via JNK- and p44\/42 MAPK-NF-\u03baB pathway but not p38 pathway in osteoblasts","volume":"31","author":"Eda","year":"2011","journal-title":"Rheumatol Int"},{"key":"2025121017321765400_keae313-B35","doi-asserted-by":"crossref","first-page":"e56045","DOI":"10.1371\/journal.pone.0056045","article-title":"IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFN\u03b3","volume":"8","author":"Foucher","year":"2013","journal-title":"PLoS One"},{"key":"2025121017321765400_keae313-B36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/25785826.2022.2137968","article-title":"Murine models of idiopathic inflammatory myopathy","volume":"46","author":"Konishi","year":"2023","journal-title":"Immunol Med"},{"key":"2025121017321765400_keae313-B37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature04734","article-title":"Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses","volume":"441","author":"Kato","year":"2006","journal-title":"Nature"},{"key":"2025121017321765400_keae313-B38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coi.2008.01.002","article-title":"MDA5\/RIG-I and virus recognition","volume":"20","author":"Takeuchi","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"2025121017321765400_keae313-B39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/imr.12091","article-title":"Virus infection, antiviral immunity, and autoimmunity","volume":"255","author":"Getts","year":"2013","journal-title":"Immunol Rev"},{"key":"2025121017321765400_keae313-B40","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/1040841X.2019.1614904","article-title":"The role of viral infections in the development of autoimmune diseases","volume":"45","author":"Hussein","year":"2019","journal-title":"Crit Rev Microbiol"},{"key":"2025121017321765400_keae313-B41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41584-020-0448-7","article-title":"Autoimmune and inflammatory diseases following COVID-19","volume":"16","author":"Galeotti","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025121017321765400_keae313-B42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11926-011-0166-x","article-title":"Pathogenesis of dermatomyositis: role of cytokines and interferon","volume":"13","author":"Kao","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"2025121017321765400_keae313-B43","doi-asserted-by":"crossref","first-page":"e001006","DOI":"10.1136\/jitc-2020-001006","article-title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","volume":"8","author":"Razak","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae313\/58225708\/keae313.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/SI\/SI97\/58225708\/keae313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/SI\/SI97\/58225708\/keae313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:32:28Z","timestamp":1765405948000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/SI\/SI97\/7687079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":43,"journal-issue":{"issue":"SI","published-online":{"date-parts":[[2024,6,3]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae313","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2024,6,3]]}}}